CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
复制标题
HIV 阴性患者的 CD20 阴性新发弥漫性大 B 细胞淋巴瘤：单个机构的匹配病例对照分析
DOI：
10.1186/1479-5876-10-84
复制
发表时间：
2012-05-03
影响因子：
7.4
通讯作者：
Jiang WQ
中科院分区：
文献类型：
--
作者：
Li YJ;Li ZM;Rao HL;Xia Y;Huang HQ;Xia ZJ;Li S;Li WY;Jiang WQ
BackgroundHIV-negative, CD20-negativede novodiffuse large B-cell lymphoma (DLBCL) patients has rarely been reported. To elucidate the nature of this entity, we retrospectively reviewed the data of 1,456 consecutivede novoDLBCL patients who were treated at Sun Yat-Sen University Cancer Center between January 1999 and March 2011.MethodsThe pathologic characteristics of CD20-negative patients, clinical features, response to initial treatment, and outcomes of 28 patients with available clinical data (n = 21) were reviewed. Then, a matched case-control (1:3) analysis was performed to compare patients with CD20-negative and -positive DLBCL.ResultsThe median age of the 28 CD20-negative DLBCL patients was 48 years, with a male-female ratio of 20:8. Seventeen of 22 (77.3%) CD20-negative DLBCL cases were of the non-germinal centre B-cell (non-GCB) subtype. High Ki67 expression (≥80%), an index of cell proliferation, was demonstrated in 17 of 24 (70.8%) cases. Extranodal involvement (≥ 1 site) was observed in 76.2% of the patients. Following initial therapy, 9 of 21 (42.9%) cases achieved complete remission, 4 (19%) achieved partial remission, 1 (4.8%) had stable disease, and 7 (33.3%) had disease progression. The median overall survival was 23 months. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 30.5% and 35%, respectively. A matched case-control analysis showed that patients with CD20-negative and -positive DLBCL did not exhibit a statistically significant difference with respect to the main clinical characteristics (except extranodal involvement), whereas the patients with CD20-positive DLBCL had a better survival outcome with 3-year PFS (P= 0.008) and OS (P= 0.008) rates of 52% and 74.1%, respectively.ConclusionsThis study suggests that HIV-negative, CD20-negativede novoDLBCL patients have a higher proportion of non-GCB subtype, a higher proliferation index, more frequent extranodal involvement, a poorer response, and a poorer prognosis to conventional treatment compared to patients with CD20-positive DLBCL. Further studies are warranted to investigate new target and optimal therapy of CD20-negativede novoDLBCL.
登录
查看更多内容
影响因子：
20.3
作者：
Hoffmann, C;Tiemann, M;Horst, HA
通讯作者：
Horst, HA
影响因子：
51.1
作者：
Pfreundschuh, Michael;Schubert, Joerg;Loeffler, Markus
通讯作者：
Loeffler, Markus
影响因子：
4.2
作者：
Horvat, Mateja;Prevodnik, Veronika Kloboves;Novakovic, Barbara Jezersek
通讯作者：
Novakovic, Barbara Jezersek
影响因子：
51.1
作者：
Pfreundschuh, Michael;Trumper, Lorenz;Loeffler, Markus
通讯作者：
Loeffler, Markus
影响因子：
3.4
作者：
NOORDUYN, LA;DEBRUIN, PC;MEIJER, CJLM
通讯作者：
MEIJER, CJLM